Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial()

PURPOSE: We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in recurrent glioblastoma (rGBM) patients would result in a synergistic therapeutic effect. We also investigated whether VEGF, VEGFR2, and HIF-1α single nucleotide polymorphisms (SNPs), circulat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Galanis, Evanthia, Anderson, S. Keith, Lafky, Jackie M., Uhm, Joon H., Giannini, Caterina, Kumar, Shaji K., Kimlinger, Teresa K., Northfelt, Donald W., Flynn, Patrick J., Jaeckle, Kurt A., Kaufmann, Timothy J., Buckner, Jan C.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3869574/
https://ncbi.nlm.nih.gov/pubmed/23833308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0708
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki